ロード中...
Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
BACKGROUND: KIT mutations are the predominant driver mutations in gastrointestinal stromal tumors (GISTs), and targeted therapy against KIT has improved treatment outcome dramatically. However, gaining secondary mutation of KIT confers drug resistance of GISTs leading to treatment failure. RESULTS:...
保存先:
| 出版年: | Cell Biosci |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7017564/ https://ncbi.nlm.nih.gov/pubmed/32082541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13578-020-0377-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|